Proportion of patients receiving platelets · People with chronic bone marrow failure
Thrombopoietin mimetic probably leads to lower proportion of participants receiving a platelet transfusion compared with placebo (moderate certainty).
1 finding from 1 review
Blood transfusion reaction · People with chronic bone marrow failure
1 finding from 1 review
Thromboembolism · People with chronic bone marrow failure
It is very uncertain whether thrombopoietin mimetic changes thromboembolism compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug reactions · People with chronic bone marrow failure
Thrombopoietin mimetic showed no clear difference in drug reactions compared with placebo (low certainty).
1 finding from 1 review
Number of red cell transfusions per participant · People with chronic bone marrow failure
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
1 finding from 1 review
Adverse events · DIC
1 finding from 1 review
Bleeding · DIC
1 finding from 1 review
Resolution of respiratory failure · DIC
1 finding from 1 review
Renal failure · DIC
1 finding from 1 review
Shock · DIC
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid showed no clear difference in overall survival ( compared with placebo or no treatment (low certainty).
1 finding from 1 review